Evidence map›Paper›PMID 30820473›Full record

ArticleCommunications biology2019

A simple high-throughput approach identifies actionable drug sensitivities in patient-derived tumor organoids.

Nhan Phan, Jenny J Hong, Bobby Tofig, Matthew Mapua, David Elashoff, Neda A Moatamed, Jin Huang, Sanaz Memarzadeh, Robert Damoiseaux, Alice Soragni

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 176 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
176citing papers in PubMed, 2 pooled it
14.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

176 citing papers in PubMed, 2 syntheses or guidelines pooled it, 268 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Re-Thinking Pharmacokinetics in Ovarian Cancer: What Do Organoids Add?International journal of molecular sciences · 2026
    Review
  16. Article
  17. Review
  18. Article
  19. Observational
  20. Article

116 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Nhan PhanDivision of Hematology-Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA.
Jenny J HongDivision of Hematology-Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA.
Bobby TofigMolecular Screening Shared Resource, California NanoSystems Institute, University of California, Los Angeles, CA, 90095, USA.
Matthew MapuaDivision of Hematology-Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA.
David ElashoffDepartment of Biostatistics, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA.
Neda A MoatamedDepartment of Pathology, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA.
Jin HuangDepartment of Obstetrics and Gynecology, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA.
Sanaz MemarzadehDepartment of Obstetrics and Gynecology, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA.
Robert DamoiseauxMolecular Screening Shared Resource, California NanoSystems Institute, University of California, Los Angeles, CA, 90095, USA.
Alice SoragniDivision of Hematology-Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA. alices@mednet.ucla.edu.
University of California, Los Angeles · USCalifornia NanoSystems Institute · USVA Greater Los Angeles Healthcare System · USVietnam National University Ho Chi Minh City · VN

Funding

UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
UCLA SPORE IN PROSTATE CANCERP50CA092131 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REITER, ROBERT E · 2002 to 2023
$42.6M
NCATS NIH HHS UL1 TR000124NCI NIH HHS P50 CA092131
6 · The paper itself

Abstract

Tumor organoids maintain cell-cell interactions, heterogeneity, microenvironment, and drug response of the sample they originate from. Thus, there is increasing interest in developing tumor organoid models for drug development and personalized medicine applications. Although organoids are in principle amenable to high-throughput screenings, progress has been hampered by technical constraints and extensive manipulations required by current methods. Here we introduce a miniaturized method that uses a simplified geometry by seeding cells around the rim of the wells (mini-rings). This allows high-throughput screenings in a format compatible with automation as shown using four patient-derived tumor organoids established from two ovarian and one peritoneal high-grade serous carcinomas and one carcinosarcoma of the ovary. Using our automated screening platform, we identified personalized responses by measuring viability, number, and size of organoids after exposure to 240 kinase inhibitors. Results are available within a week from surgery, a timeline compatible with therapeutic decision-making.

Indexed as

Cell ProliferationCell SurvivalHumansNeoplasmsOrganoidsPrecision MedicineProtein Kinase InhibitorsReproducibility of ResultsTissue Culture TechniquesTumor MicroenvironmentProtein Kinase Inhibitors

Identifiers

PMID30820473
PMCPMC6389967
OpenAlexW2917438927

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.